Select Page
  1. Home
  2.  » 
  3. Events
  4.  » World Orphan Drug Congress USA

World Orphan Drug Congress USA

Schedule to meet with Catalent at World Orphan Drug Congress

Date: August 24-26, 2020
Location: Virtual Conference


Thomas VanCott, Ph.D., Chief Technology and Strategy Officer at Catalent Gene TherapyThomas VanCott, Ph.D.
Global Head of Product Development, Catalent Cell & Gene Therapy
Session Title: Creating Commercial-ready & Scalable Solutions for Gene Therapy Development & Manufacturing
Date: Monday, August 24, 2020
Time: 12:50 PM to 1:10 PM ET
Abstract: The therapeutic promise of gene therapies can be hampered by the challenges of developing a reliable and scalable manufacturing process. In this session, the complexities from raw material supply through drug product manufacturing, including planning early for a commercial-ready process will be presented.


Cornell Stamoran, Ph.D.
Vice President of Corporate Strategy, Catalent
Session Title: Preparing for Success: Early Development Considerations for Orphan Drug Commercialization
Date: Tuesday, August 25, 2020
Time: 12:50 PM to 1:10 PM ET
Abstract: Finding a molecule that can treat or cure an orphan disease is an enormous undertaking, consuming cost, time, and resources. After validating the molecule’s activity in appropriate animal models, the last thing most companies want to do is invest any extra time in the further development of the molecule and formulation before going straight into human trials. Yet it’s exactly at this stage where intentional design decisions can have the greatest impact on the product’s potential – its risk profile, the speed it goes through development and scale-up to commercial, and ultimately its usability by patients.

We will examine this from three perspectives:

  • Making the right choices to increase the products developability
  • To improve its manufacturability, and
  • To ultimately enhance its usability by patients